Potassium Chloride Ph. Eur., Sodium Hydrogen Carbonate Pheur, Sodium Chloride Ph. Eur.

6 trials 3 recruiting BHaematology

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

2 Completed trials

6 Sponsors

12 Countries

Phase III

Phase II

Phase IV

Phase I (FiH)

Phase III: 2 Phase II: 1 Phase IV: 2 Phase I (FiH): 1

Oversight events:

6 temporary halts 1 unexpected event across 1 trial

View oversight register →

Indications tested

Cardiac amyloidosis 1 Myotonic dystrophy 1

Sponsors using this IMP

Alexion Pharmaceuticals Inc. 1 Dyne Therapeutics Inc. 1 Leids Universitair Medisch Centrum (LUMC) 1 Les Hopitaux Universitaires De Strasbourg 1 Moderna Inc. 1 Novo Nordisk A/S 1

All trials

6 total

Efficacy, Safety, and Tolerability of DYNE-101 in Participants with Myotonic Dystrophy Type 1 Pending

2025-522957-20-00 Phase III 7 countries Dyne Therapeutics Inc.
A study to investigate the safety and efficacy of mRNA-3927 in participants with genetically confirmed propionic acidemia Recruiting

2022-502910-10-00 Phase I (FiH) 4 countries Moderna Inc.
Optimization of pain management for acute renal colic in the Emergency Department – The OPTIMIZED trial Recruiting

2025-521316-19-00 Phase IV 1 country Leids Universitair Medisch Centrum (LUMC)
Evaluation of 200 mg of Rituximab every 6 months as maintenance treatment of Rituximab-treated patients with rheumatoid arthritis: a non-inf… Recruiting

2024-519991-18-00 Phase IV 1 country Les Hopitaux Universitaires De Strasbourg
A research study to look at long-term treatment with a medicine called NNC6019-0001 for people who have heart failure due to transthyretin a… Ended

2022-502605-15-00 Phase II 7 countries Novo Nordisk A/S
A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis. Ended

2022-503072-84-00 Phase III 8 countries Alexion Pharmaceuticals Inc.

Showing 1–6 of 6 trials

← All drugs A–Z